Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced that Eisai Laboratorios Ltda., a subsidiary of Eisai Inc., has filed for marketing authorization of BELVIQ® as a treatment for chronic weight management with the Brazilian Health Surveillance Agency (Anvisa). Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock opened at $6.71 in last session, and closed at $6.74, while the day range of ARNA stock is $6.55 – $6.84. The stock showed a negative weekly performance of -1.32%.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced the appointment of Alexander J. Denner, Ph.D. to a two-year term on the Company’s Board of Directors, effective immediately. With the addition of Dr. Denner, who serves as the chief investment officer and founding partner of Sarissa Capital Management LP, the Board now comprises nine directors, eight of whom are independent. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock opened at $8.69, in last session and closed at $8.73, by gaining 1.51%. The 52 week range of ARIA is $2.15 – $23.00. Company’s market capitalization is $1.62billion.
Trade-Ideas LLC identified Orexigen Therapeutics Inc. (NASDAQ:OREX) as a “perilous reversal” candidate. Orexigen Therapeutics, Inc. (NASDAQ:OREX) stock advanced 0.99% and finished the last session at $7.14. The EPS of the stock remained -1.01. Company’s market capitalization is $723.81million.
VIVUS, Inc. (NASDAQ:VVUS)’s shares gained 0.88% to $6.86. The company will report financial results for the fourth quarter and year ended Dec. 31, 2013 after the Market closes on Feb. 24, 2014. VIVUS, Inc. (NASDAQ:VVUS) stock opened the session at $6.84, and closed the session at $6.81. The 52 week range of the VVUS stock remained $6.43 – $15.62 and the day range was $6.71 – $6.91.